Project Grant R61HL181756
Award Date 9/1/25
Completion Date 7/31/27
Dollars Obligated $611K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Farmington, CT 06030, USA
Similar Awards
- This Project Grant award of $615,006.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will support research to reclassify and determine the pathophysiology of variants of unknown/uncertain significance (VUS) in the TNNT2 gene, which encodes an essential component of the cardiac sarcomere. The key products and services to be delivered include: Comprehensive functional studies of 251 TNNT2 VUS using a human induced pluripotent stem cell-derived...
- This Project Grant award of $520,483 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at The University of Texas Southwestern Medical Center to develop adeno-associated virus (AAV)-based gene therapy tools for efficient delivery of therapeutic cargos to the atrioventricular node (AVN) of the cardiac conduction system. The long-term goal is to devise new therapeutic approaches for cardiac dysrhythmias. The key objectives are to...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $694,754 to The Washington University to investigate the connections between genotype, molecular/cellular dysfunction, and small molecule treatments for key troponin cardiomyopathy mutations. The 5-year project aims to build a mechanistic understanding of how specific genetic mutations impact contractile function at the molecular, cellular, and tissue levels...
- This federal Project Grant award of $621,546.00, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), focuses on observing the single molecule dynamics of the catalytic subunit of cAMP-dependent protein kinase A (PKA-C) under both normal and disease-associated conditions. The primary objectives are to: 1) Engineer a single-walled carbon nanotube field effect transistor (SWNT FET) system to record PKA-C single molecule...
- The National Heart, Lung, and Blood Institute (NHLBI), under CFDA Program 93.837 Cardiovascular Diseases Research, awarded a $776,791 Project Grant to The Washington University to study the impact of sequence changes on key intrinsically disordered regions of cardiac troponin. This research aims to elucidate how mutations and post-translational modifications affecting disordered regions of the troponin complex can disrupt cardiac muscle contraction regulation, leading to diseases like...
- The Project Grant award of $564,121 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will support research to develop peptide surface-functionalized lipid nanoparticles (PepLNPs) for pulmonary delivery that can reach airway basal cells and use base editing technology to correct specific CFTR gene mutations associated with cystic fibrosis. The goal is to achieve permanent correction of lung disease in cystic fibrosis patients through one-time,...
- This federal Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the use of NNMT inhibition to treat heart failure. The $736,089 grant supports research to determine if increased NNMT activity, leading to NAD+ deficiency, is central to the pathophysiology of both heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). The...
- This $385,381 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of dynamic biological hydrogels to modulate cardiac remodeling following myocardial infarction. The primary goals are to: 1) Improve the mechanical stability and stiffness of cardiac extracellular matrix hydrogels compared to existing therapies, and 2) Leverage changes in extracellular matrix composition to promote a more regenerative...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $243,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Cincinnati's Sponsored Research Services Division. The grant will fund a 2-year project to engineer advanced RNA biodevices that leverage CRISPR and ADAR gene-editing technologies. The goal is to improve the efficiency and specificity of converting resident cardiac fibroblasts into functional cardiomyocytes, in order to boost...
- The Project Grant award titled "STRESS-INDUCED TRNA-DERIVED SMALL RNAS IN CARDIAC FIBROSIS" is funded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) in the amount of $739,474.00. The award, with a performance period from August 18, 2025 to May 31, 2030, supports research conducted by The General Hospital Corporation (Massachusetts General Hospital) to investigate the anti-fibrotic roles of a tRNA-derived small RNA (ASP-GTC-3'TDR) in...